Huub Schellekens, Professor of pharmaceutical biotechnology at Utrecht University: "We need 20 billion doses for the entire world population"
PDF) Making individualized drugs a reality
PDF) Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates
PDF) Immunogenicity of mAbs in non-human primates during nonclinical safety assessment | Beatriz Silva Lima - Academia.edu
The First Biosimilar Epoetin: But How Similar Is It?
Dure medicijnen mogelijk betaalbaar door Utrechtse uitvinding | De Utrechtse Internet Courant
Huub Schellekens - HR Business Partner - Feenstra | LinkedIn
SciELO - Saúde Pública - Hubs to spread technology and save lives Hubs to spread technology and save lives
Heidi Schellekens - massage & bewustwording Utrecht | Utrecht
Huub Schellekens – Studium Generale Universiteit Utrecht
Protection of Rats against Pseudorabies Virus Infection by γ-Interferon
Biosimilars bieden oplossing voor stijgende kost onco- en hematologische behandelingen - Actualiteit - Belgian Oncology & Hematology News - Artsenkrant.com
Immunogenicity and glycosylation: The key issues for biosimilars - ppt video online download
Medicijnen voor derde wereld voor 5 procent van de prijs'
Zo kan Nederland zich beter wapenen tegen epidemieën
Zomerportret 1. Huub Schellekens: 'Iedereen moet weer gaan doen waar hij goed in is' | medischcontact
Zomerportret 1. Huub Schellekens: 'Iedereen moet weer gaan doen waar hij goed in is' | medischcontact
Immunogenicity and aggregation of therapeutic proteins - American ...
PDF) Challenges in standardizing safety assessments of biopharmaceuticals, the case of EPREX Associated Pure Red Cell Aplasia | Toine Pieters - Academia.edu
BIOLOGICALS UIT DE BIO-NESPRESSO?
Professor Schellekens maakt medicijnen zelf - Zembla - BNNVARA
Biosimilars are as safe and efficient for use as cancer medication as the original - News - Utrecht University
Huub Schellekens, Professor of pharmaceutical biotechnology at Utrecht University: "We need 20 billion doses for the entire world population"
Peperduur medicijn voor een schijntje nagemaakt | De Volkskrant
Pharmaceutical Technology Europe - August 2010 - What is Hindering the Uptake of Biosimilars
PDF) Biosimilar therapeutics—What do we need to consider?
Evaluation of the suitability of a Sprague Dawley rat model to assess intravenous iron preparations
